A Study of PYX-201 in Advanced Solid Tumors

Inclusion Criteria

• •Inclusion
• •1. Histologically or cytologically confirmed solid tumors including locally advanced/metastatic HR+ and HER2- breast cancer (post CDK4/6 inhibitor +/- ET, ≤ 2 lines systemic therapy), TNBC (1-3 prior lines including post ADC topo-1 payload), HNSCC (1-2 prior lines including post PD-L1/PD1 and platinum based therapy), and other solid tumor types (≤ 2 lines systemic therapy).
• •2. Male or non-pregnant, non-lactating female participants age ≥18 years.
• •3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1.
• •4. Participant must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
• •5. Life expectancy of \>3 months, in the opinion of the Investigator.
• •6. Corrected QTcF \<470 msec.
• •7. Adequate hematologic function.
• •8. Adequate hepatic function.
• •9. Adequate renal function.
• +20 more criteria